Monoclonal antibodies, often called mAbs, have become one of the most important tools in modern medicine. They are widely used in cancer therapy, autoimmune diseases, and infectious disease research. Because of this rising demand, many biotech companies are working to improve production efficiency and quality.
If you are exploring how therapeutic antibodies are made or planning to buy monoclonal antibodies for research use, it helps to understand what actually happens behind the scenes. The journey from a living cell line to a purified antibody product is complex, and each step presents its own set of challenges.
Upstream and downstream processing are the two major phases of mAb production. Upstream focuses on growing cells that produce the antibody, while downstream focuses on purifying and refining it into a safe, usable product.
What Are The Challenges In Upstream Processing?
Upstream processing plays an important role in deciding how efficiently a monoclonal antibody is actually produced, even before purification begins.
Here are 5 common issues that often come up in upstream processing
Low Expression Titers
You often face low protein production from CHO cell lines, which directly limits overall antibody yield.
You also need to optimize feed strategies carefully to improve cell productivity.
However, even small changes in nutrients or conditions may not always improve results, so you need to constantly balance them.
Contamination Risks
You need to keep the cell culture completely sterile throughout the process. You also need to handle multiple steps carefully, as even minor contamination can affect the entire batch.
Another problem is that contamination is often hard to detect early, which can lead to large-scale production loss.
Process Variability
You may face changes in nutrient levels or cell health during monoclonal antibody production using CHO cell culture systems, where cells are grown in bioreactors to produce the target antibody protein.
However, because cells are living systems, you can still see changes in yield and consistency.
Incorrect Chain Pairing
You can face mismatched heavy and light chains in complex antibody structures.
You also need to ensure correct assembly to avoid unwanted variants. Otherwise, wrong pairing can create impurities and lower product quality.
Scale-Up Limitations
Sometimes, heavy and light chain pairs incorrectly assemble when you are working with complex antibodies.
This wrong assembly introduces impurities into the batch and directly weakens the quality and effectiveness of your final product
What Are The Challenges In Downstream Processing?
Downstream processing is the stage where monoclonal antibodies are purified, separated, and prepared for use. Even if upstream production is strong, this phase decides how clean, stable, and usable the final product will be.
Purification Bottlenecks
When upstream processes produce very high antibody levels, the purification system can become overloaded. This is often called a bottleneck. It simply means the purification process cannot handle the large amount of material being produced. To fix this, faster chromatography methods are used, but they need careful tuning to work properly.
Removal of Impurities
After cell culture, the mixture has antibodies along with unwanted materials like Host Cell Proteins (HCPs), DNA fragments, and damaged or incomplete antibodies. When you work with antibody samples, make sure to remove the impurities.
Product Aggregation & Degradation
Antibodies are sensitive molecules. During purification steps such as low pH viral inactivation or filtration, they can clump together or break down. This is called aggregation or degradation. Aggregated antibodies may lose their function or even trigger immune reactions in patients.
Yield Loss
At every purification step, a small portion of the antibody is lost. While each loss may seem minor, they add up across multiple stages, like filtration and chromatography. By the end of the process, the total amount of usable antibody can be significantly lower than what was originally produced.
How These Challenges Are Managed
To solve these problems, the industry uses a few advanced methods.
Single-use technologies are a big help here. They cut down contamination risks and save you the hassle of cleaning and setting up equipment between runs. Continuous processing, like continuous chromatography, keeps things moving without the usual batch delays.
0 Comments